PD1 signal transduction pathways in T cells
Fecha
2017Autor
Versión
Acceso abierto / Sarbide irekia
Tipo
Artículo / Artikulua
Versión
Versión publicada / Argitaratu den bertsioa
Impacto
|
10.18632/oncotarget
Resumen
The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or ...
[++]
The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction. [--]
Materias
PD-L1,
PDL1,
PD1,
B7-H1,
Cancer
Editor
Impact Journals
Publicado en
Oncotarget, 2017, 8 (31), pp. 51936-51945
Departamento
Universidad Pública de Navarra. Departamento de Ciencias de la Salud /
Nafarroako Unibertsitate Publikoa. Osasun Zientziak Saila
Versión del editor
Entidades Financiadoras
MGC is funded by a Government of Navarre PhD fellowship (BMED 033-2014); MZ is funded by a Gobierno de Navarra Project grant (GN 33/14) and a ‘Precipita’ crowdfunding project grant from Fundación Española para la Ciencia y la Tecnología (FECYT). MIV is funded by a Sara Borrel post-doctoral fellowship. DE is funded by a 'Miguel Servet' Fellowship (CP12/03114) from the Instituto de Salud Carlos III (ISCIII), Spain. GK is funded by a ‘Proyecto Tractor ProCel’ from the Government of Navarre. The authors gratefully acknowledge the ‘Sandra Ibarra’ Foundation, the ‘Navarrese Association against Breast Cancer’ (SARAY), ‘Caixa Foundation’ and ISCIII (FIS. PI14/00579 project grant) for their financial support.